Adynxx, Inc.
OTC: ADYX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Richard Orr
- Employees
- 6
- Headquarters
- San Francisco, United States
- IPO year
- 1998
- Market cap
- $581.0
- Website
- https://www.adynxx.com
Loading ADYX…
Loading profile data…Frequently asked questions about ADYX
What does Adynxx, Inc. (ADYX) do?
Adynxx, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating and commercializing novel transcription factor decoy technologies to combat pain and inflammatory conditions. Central to its efforts is the AYX platform of transcription factor decoys, which includes brivoligide, currently progressing through Phase II clinical developm...
Where does ADYX trade?
Adynxx, Inc. (ADYX) trades on the Other OTC.
What sector is ADYX in?
Adynxx, Inc. (ADYX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Adynxx, Inc.?
Richard Orr is the chief executive officer of Adynxx, Inc. (ADYX).
Where is Adynxx, Inc. headquartered?
Adynxx, Inc. is headquartered in United States.
Does ADYX pay a dividend?
Adynxx, Inc. (ADYX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ADYX go public?
Adynxx, Inc. (ADYX) completed its initial public offering in 1998.